H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $260 from $200 and keeps a Buy rating on the shares. The company’s preliminary 2025 revenue numbers show commercial strength, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $223 from $148 at Piper Sandler
- Axsome Therapeutics initiate FORWARD Phase 3 trial of AXS-14
- Axsome Therapeutics price target raised to $209 from $157 at Baird
- Axsome Therapeutics price target raised to $193 from $157 at Wells Fargo
- Axsome Therapeutics: Strong Commercial Execution and De-Risked Pipeline Support Buy Rating and Long-Term Growth